PLUS THERAPEUTICS, INC.
Business
Plus Therapeutics is a U.S. healthcare company developing precision diagnostics and targeted radiopharmaceuticals for central nervous system cancers. The company offers the CNSide laboratory-developed test platform for detecting metastasized tumor cells and is advancing rhenium-186 obisbemeda as a localized radiotherapy for glioblastoma, leptomeningeal metastases, and pediatric brain cancers via direct brain delivery. The company also licenses and develops rhenium-188 nanoliposome technology for intra-arterial radioembolization of solid organ cancers. Plus Therapeutics operates through clinical trials funded partly by government grants, with commercialization of its CNSide test underway through payor agreements and state licensure.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 5 | 6 | 5 | — | — | |
| Research and development | 8 | 11 | 10 | 10 | — | |
| General and administrative | 12 | 10 | 9 | 10 | 7 | |
| Total operating expenses | 21 | 21 | 18 | 20 | 12 | |
| Operating loss | −15 | −15 | −13 | −20 | −12 | |
| Financing expense | −3 | −4 | — | — | — | |
| Change in fair value of derivative instruments | −3 | 6 | — | — | — | |
| Warrant issuance costs | −964,000 | −486,000 | — | — | — | |
| Interest income | 116,000 | 273,000 | 400,000 | 147,000 | 19,000 | |
| Interest expense | −548,000 | −179,000 | −395,000 | — | — | |
| Total other income (expense) | −7 | 2 | 5,000 | −563,000 | −907,000 | |
| Net loss | −22 | −13 | −13 | −20 | −13 | |
| Net loss per share of common stock - basic | −0.29 | −1.95 | −4.24 | −11.58 | −1.11 | |
| Net loss per share of common stock - diluted | −0.29 | −2.34 | −4.24 | −11.58 | −1.11 | |
| Weighted average number of shares of common stock outstanding - basic | 78 | 7 | 3 | 2 | 12 | |
| Weighted average number of shares of common stock outstanding - diluted | 78 | 8 | 3 | 2 | 12 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 76,000 | 9 | 18 | 18 | |
| Restricted cash and cash equivalents | 5 | — | — | — | — | |
| Investments | 4 | 4 | — | — | — | |
| Grant receivable | 322,000 | 571,000 | — | — | — | |
| Other current assets | 2 | 1 | 1 | 4 | 1 | |
| Total current assets | 15 | 5 | 10 | 22 | 20 | |
| Property and equipment, net | 257,000 | 448,000 | 906,000 | 1 | 1 | |
| Operating lease right-use-of assets | 70,000 | 73,000 | 202,000 | 248,000 | 341,000 | |
| Goodwill | 372,000 | 372,000 | 372,000 | 372,000 | 372,000 | |
| Intangible assets, net | 333,000 | 469,000 | 42,000 | 94,000 | 51,000 | |
| Other assets | 123,000 | 12,000 | 32,000 | 12,000 | 16,000 | |
| Total assets | 16 | 7 | 11 | 24 | 22 | |
| Accounts payable and accrued expenses | 6 | 11 | 7 | 10 | 4 | |
| Investor liability pursuant to Letter Agreement | 5 | — | — | — | — | |
| Operating lease liability | 56,000 | 44,000 | 120,000 | 110,000 | 111,000 | |
| Deferred grant liability | 927,000 | 927,000 | — | — | — | |
| Other liabilities | 159,000 | — | — | — | — | |
| Line of credit | 750,000 | 3 | — | — | — | |
| Total current liabilities | 12 | 16 | 11 | 12 | 6 | |
| Noncurrent operating lease liability | 15,000 | 31,000 | 85,000 | 141,000 | 269,000 | |
| Total liabilities | 12 | 16 | 13 | 17 | 11 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding as of December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock, $0.001 par value; 2,000,000,000 shares authorized; 138,934,281 shares issued and 138,675,856 outstanding as of December 31, 2025, 100,000,000 shares authorized; 6,154,758 shares issued and 5,896,333 outstanding as of December 31, 2024, respectively | 139,000 | 6,000 | 5,000 | 2,000 | 16,000 | |
| Treasury stock (at cost), 258,425 shares as of December 31, 2025 and 2024, respectively | −500,000 | −500,000 | −126,000 | — | — | |
| Additional paid-in capital | 520 | 485 | 479 | 474 | 458 | |
| Accumulated deficit | −516 | −493 | −481 | −467 | −447 | |
| Total stockholders' equity (deficit) | 4 | −9 | −1 | 6 | 11 | |
| Total liabilities and stockholders' equity | 16 | 7 | 11 | 24 | 22 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 445,000 | 872,000 | 628,000 | 619,000 | 395,000 | |
| Accretion of discount on short-term investments | −9,000 | −111,000 | — | — | — | |
| Noncash financing expenses | 3 | 4 | — | — | — | |
| Stock compensation expense | 2 | 550,000 | 569,000 | 606,000 | 606,000 | |
| Gain on sale of assets | −16,000 | — | 2,000 | — | — | |
| Grant receivable | 249,000 | −571,000 | — | — | — | |
| Other assets | −763,000 | 218,000 | — | — | — | |
| Accounts payable and accrued expenses | −6 | 5 | −4 | 6 | 2 | |
| Other liabilities | 159,000 | — | — | — | — | |
| Change in operating lease liabilities | −66,000 | −130,000 | −117,000 | −129,000 | — | |
| Deferred grant liability | — | −997,000 | 281,000 | 2 | — | |
| Net cash used in operating activities | −21 | −11 | −13 | −13 | −10 | |
| Purchases of property and equipment | −67,000 | −146,000 | −160,000 | — | — | |
| Proceeds from sale of property and equipment | 30,000 | — | — | 0 | 62,000 | |
| Purchases of intangible assets | — | −545,000 | — | — | 0 | |
| Purchases of short-term investments | −9 | −16 | — | — | — | |
| Proceeds from redemption of short-term investments | 4 | 12 | — | — | — | |
| Proceeds from sales of short-term investments | 5 | 12 | — | — | — | |
| Net cash used in investing activities | −854,000 | −4 | −160,000 | −759,000 | −82,000 | |
| Principal payments of term loan obligation | — | −4 | −2 | −2 | −268,000 | |
| Proceeds from credit facility | 750,000 | 3 | — | — | — | |
| Repayment of credit facility | −3 | — | — | — | — | |
| Payment of financing costs | −2 | — | — | — | — | |
| Proceeds from issuance of notes payable and warrants | 4 | — | — | — | — | |
| Repayment of notes payable | −4 | — | — | — | — | |
| Proceeds from sale of common stock, pre-funded warrants, and warrants | 16 | 7 | — | — | — | |
| Proceeds from sale of common stock under Lincoln Park Purchase Agreement | 23 | — | 6 | 16 | 19 | |
| Payment to investors pursuant to Letter Agreement | −3 | — | — | — | — | |
| Offering costs for sale of common stock | −231,000 | — | −348,000 | −773,000 | 0 | |
| Purchase of treasury stock | — | −374,000 | −126,000 | — | — | |
| Net cash provided by financing activities | 30 | 6 | 3 | 13 | 20 | |
| Net increase (decrease) in cash and cash equivalents | 9 | −8 | −10 | −280,000 | 10 | |
| Interest | — | 32,000 | 222,000 | 327,000 | 388,000 | |
| Unpaid offering cost | 252,000 | — | 174,000 | 0 | 219,000 | |
| Unpaid liability to investors pursuant to Letter Agreement | 5 | — | — | — | — | |
| Exchange of warrants for notes payable | 4 | — | — | — | — | |
| Redemption of notes by issuance of common stock, pre-funded warrants and warrants | 4 | — | — | — | — | |
| Right-of-use assets acquired by assuming operating lease liabilities | 62,000 | — | 71,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is PLUS THERAPEUTICS, INC.'s CIK number?
PLUS THERAPEUTICS, INC.'s SEC CIK number is 0001095981 (1095981). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find PLUS THERAPEUTICS, INC.'s SEC filings?
All of PLUS THERAPEUTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did PLUS THERAPEUTICS, INC. last report earnings?
PLUS THERAPEUTICS, INC. (PSTV) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-226747). This is PLUS THERAPEUTICS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is PLUS THERAPEUTICS, INC.'s most recent earnings 8-K?
PLUS THERAPEUTICS, INC.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001193125-26-226747. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View PLUS THERAPEUTICS, INC.'s latest earnings 8-K →
Look up any company's CIK number →